BackMacrogenics Overview

Macrogenics Current Cash

Macrogenics's current cash is $67M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$66.52M
↓ 54.31% YoYΔ $-79.05M vs prior year quarter

Peer average

Loading

Macrogenics Current Cash History

Loading

Macrogenics vs. peers: Current Cash Comparison

Loading

Macrogenics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Macrogenics (MGNX) FAQ

As of the most recent data (March 2026), MGNX shows a current cash of $67M. That compares with $150M in the prior-year period — down 54.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MGNX's current cash is now $67M (was $150M) — a 54.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Macrogenics is outperforming or lagging.

Tracking MGNX's current cash over time shows whether Macrogenics is scaling, shrinking, or reshaping that part of the business. The current reading is $67M That compares with $150M in the prior-year period — down 54.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Macrogenics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $67M) with ownership activity and broader fundamentals.

Macrogenics's current cash is $67M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.